proxyvotesnow.com

Home › Companies › Praxis Precision Medicines, Inc. › 2025-2026

Praxis Precision Medicines, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Praxis Precision Medicines, Inc.’s Form 8-K, filed 2026-06-12 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 5Ballot items
  • 303Asset managers
  • 2,108Fund votes
  • 2026-06-10Meeting date

Proxy season: 2024-2025 2025-2026

Explore Praxis Precision Medicines, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Praxis Precision Medicines, Inc.

These tallies are Praxis Precision Medicines, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-12 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Praxis Precision Medicines, Inc. — official shareholder meeting results, meeting held 2026-06-10
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Gregory Norden 24,597,327---- 310,9371,815,967 Majority: yes
Elect Director: Marcio Souza 24,771,396---- 136,8681,815,967 Majority: yes
Elect Director: William Young 21,293,535---- 3,614,7291,815,967 Majority: yes
Proposal 2: Ratification of Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm 26,667,37639,28517,570 --0 Majority: yes
Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers, with the votes cast as follows: 24,054,017824,31829,929 --1,815,967 Majority: yes

Source: Praxis Precision Medicines, Inc., Form 8-K, filed with the SEC on 2026-06-12 — read the filing on EDGAR.

How asset managers voted at the Praxis Precision Medicines, Inc. 2025-2026 meeting

Each item below shows how the 303 asset managers that disclosed a Praxis Precision Medicines, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2026 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 16 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 24,054,017AGAINST: 824,318

Praxis Precision Medicines, Inc.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers, with the votes cast as follows:”): 24,054,017 for, 824,318 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 27,859,514 outstanding shares: 86% for, 3% against (89% of the company cast a for/against vote).

The 302 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 98%
FOR: 97.6%AGAINST: 2.4%ABSTAIN: 0.0%NOT VOTED: 0.0%
Largest asset managers voting on “To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed ” at Praxis Precision Medicines, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Janus Henderson6,677,4505,542 00For
Fidelity4,351,0240 00For
Vanguard2,242,1011 00For
BlackRock2,090,0435,632 00For
Orbis Allan Gray Ltd2,077,4470 00For
PERCEPTIVE ADVISORS LLC1,752,5270 00For
T. Rowe Price1,399,3630 00For
JANUS INVESTMENT FUND1,105,5980 00For
State Street830,5434,850 00For
GEODE CAPITAL MANAGEMENT, LLC650,8800 00For
DRIEHAUS CAPITAL MANAGEMENT LLC643,0670 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.585,5970 00For
DEERFIELD MANAGEMENT COMPANY, L.P.554,7220 00For
Charles Schwab432,8160 00For
Cormorant Asset Management, LP347,7240 00For
Hood River Capital Management LLC346,9870 00For
Vivo Capital, LLC338,8950 00For
RA CAPITAL MANAGEMENT, L.P.335,1320 00For
Soleus Capital Management, L.P.331,9810 00For
FRANKLIN ADVISERS INC271,2570 00For
PICTET ASSET MANAGEMENT SA264,1170 00For
AustralianSuper Pty Ltd0227,786 00Against
Northern Trust217,1821,018 00For
Aberdeen217,2520 00For
Manager Directed Portfolios211,0070 00For

Showing the 25 largest of 302 asset managers. See all 302 in the interactive database.

2. To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Gregory Norden

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 24,597,327WITHHELD: 310,937

Praxis Precision Medicines, Inc.’s own tally for this item (“Elect Director: Gregory Norden”): 24,597,327 for, 310,937 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 27,859,514 outstanding shares: 88% for, 1% withheld (89% of the company cast a for/withheld vote).

The 90 asset managers below cast 100% of the shares they voted on this item FOR (9,284,367 for, 0 against).

FOR 99.4%
FOR: 9,284,367 (99.4%)ABSTAIN: 53,032 (0.6%)
Largest asset managers voting on “To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respec” at Praxis Precision Medicines, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity2,248,5560 00For
Vanguard2,028,4720 3,7550For
BlackRock1,179,0300 00For
JANUS INVESTMENT FUND1,105,5980 00For
T. Rowe Price559,6890 00For
State Street333,4820 00For
Charles Schwab216,3650 00For
Manager Directed Portfolios211,0070 00For
Bridge Builder Trust140,9000 00For
FRANKLIN STRATEGIC SERIES120,1350 00For
DRIEHAUS MUTUAL FUNDS119,1290 00For
Equitable69,2410 18,5600For
American Century86,9620 00For
Goldman Sachs64,7570 00For
TIAA58,6740 00For
Jackson National45,5380 00For
Aberdeen44,7680 00For
Invesco38,5410 00For
JPMorgan38,3570 00For
MUTUAL FUND SERIES TRUST38,3070 00For
QUANTITATIVE MASTER SERIES LLC36,2160 00For
AIG/SunAmerica33,2070 00For
MERIDIAN FUND INC28,0700 00For
Lincoln Financial25,2500 00For
JANUS ASPEN SERIES24,6220 00For

Showing the 25 largest of 90 asset managers. See all 90 in the interactive database.

3. To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Marcio Souza

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 24,771,396WITHHELD: 136,868

Praxis Precision Medicines, Inc.’s own tally for this item (“Elect Director: Marcio Souza”): 24,771,396 for, 136,868 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 27,859,514 outstanding shares: 89% for, 0.5% withheld (89% of the company cast a for/withheld vote).

The 90 asset managers below cast 100% of the shares they voted on this item FOR (9,304,326 for, 0 against).

FOR 99.6%
FOR: 9,304,326 (99.6%)ABSTAIN: 33,073 (0.4%)
Largest asset managers voting on “To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respec” at Praxis Precision Medicines, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity2,248,5560 00For
Vanguard2,029,8710 2,3560For
BlackRock1,179,0300 00For
JANUS INVESTMENT FUND1,105,5980 00For
T. Rowe Price559,6890 00For
State Street333,4820 00For
Charles Schwab216,3650 00For
Manager Directed Portfolios211,0070 00For
Bridge Builder Trust140,9000 00For
FRANKLIN STRATEGIC SERIES120,1350 00For
DRIEHAUS MUTUAL FUNDS119,1290 00For
Equitable87,8010 00For
American Century86,9620 00For
Goldman Sachs64,7570 00For
TIAA58,6740 00For
Jackson National45,5380 00For
Aberdeen44,7680 00For
Invesco38,5410 00For
JPMorgan38,3570 00For
MUTUAL FUND SERIES TRUST38,3070 00For
QUANTITATIVE MASTER SERIES LLC36,2160 00For
AIG/SunAmerica33,2070 00For
MERIDIAN FUND INC28,0700 00For
Lincoln Financial25,2500 00For
JANUS ASPEN SERIES24,6220 00For

Showing the 25 largest of 90 asset managers. See all 90 in the interactive database.

4. To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: William Young

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD 15%
FOR: 21,293,535WITHHELD: 3,614,729

Praxis Precision Medicines, Inc.’s own tally for this item (“Elect Director: William Young”): 21,293,535 for, 3,614,729 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 27,859,514 outstanding shares: 76% for, 13% withheld (89% of the company cast a for/withheld vote).

The 90 asset managers below cast 100% of the shares they voted on this item FOR (8,404,448 for, 0 against).

FOR 90%10%
FOR: 8,404,448 (90.0%)ABSTAIN: 932,951 (10.0%)
Largest asset managers voting on “To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respec” at Praxis Precision Medicines, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity2,248,5560 00For
Vanguard1,965,6250 66,6020For
BlackRock1,179,0300 00For
JANUS INVESTMENT FUND1,083,1210 22,4770For
T. Rowe Price559,6890 00For
State Street333,4820 00For
Charles Schwab216,3650 00For
Manager Directed Portfolios211,0070 00For
Bridge Builder Trust11,0890 129,8110Abstain
FRANKLIN STRATEGIC SERIES120,1350 00For
DRIEHAUS MUTUAL FUNDS00 119,1290Abstain
Equitable69,2410 18,5600For
American Century00 86,9620Abstain
Goldman Sachs1,1580 63,5990Abstain
TIAA58,6740 00For
Jackson National16,2940 29,2440Abstain
Aberdeen00 44,7680Abstain
Invesco38,5410 00For
JPMorgan38,3570 00For
MUTUAL FUND SERIES TRUST38,3070 00For
QUANTITATIVE MASTER SERIES LLC36,2160 00For
AIG/SunAmerica00 33,2070Abstain
MERIDIAN FUND INC00 28,0700Abstain
Lincoln Financial19,3660 5,8840For
JANUS ASPEN SERIES24,6220 00For

Showing the 25 largest of 90 asset managers. See all 90 in the interactive database.

5. TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 26,667,376AGAINST: 39,285

Praxis Precision Medicines, Inc.’s own tally for this item (“Proposal 2: Ratification of Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's indepe”): 26,667,376 for, 39,285 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 27,859,514 outstanding shares: 96% for, 0.2% against (96% of the company cast a for/against vote).

The 90 asset managers below cast 100% of the shares they voted on this item FOR (9,337,253 for, 0 against).

FOR 99.9%
FOR: 9,337,253 (100.0%)ABSTAIN: 147 (0.0%)
Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FO” at Praxis Precision Medicines, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity2,248,5560 00For
Vanguard2,032,2280 00For
BlackRock1,179,0300 00For
JANUS INVESTMENT FUND1,105,5980 00For
T. Rowe Price559,6890 00For
State Street333,4820 00For
Charles Schwab216,3650 00For
Manager Directed Portfolios211,0070 00For
Bridge Builder Trust140,9000 00For
FRANKLIN STRATEGIC SERIES120,1350 00For
DRIEHAUS MUTUAL FUNDS119,1290 00For
Equitable87,8010 00For
American Century86,9620 00For
Goldman Sachs64,7570 00For
TIAA58,6740 00For
Jackson National45,5380 00For
Aberdeen44,7680 00For
Invesco38,5410 00For
JPMorgan38,3570 00For
MUTUAL FUND SERIES TRUST38,3070 00For
QUANTITATIVE MASTER SERIES LLC36,2160 00For
AIG/SunAmerica33,2070 00For
MERIDIAN FUND INC28,0700 00For
Lincoln Financial25,2500 00For
JANUS ASPEN SERIES24,6220 00For

Showing the 25 largest of 90 asset managers. See all 90 in the interactive database.

Largest Praxis Precision Medicines, Inc. shareholders voting in 2025-2026

Ranked by the number of Praxis Precision Medicines, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 27,859,514 shares outstanding at the time of that meeting.

Top Praxis Precision Medicines, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1Janus Henderson 23.99%
2Fidelity 15.62%
3Vanguard 8.05%
4BlackRock 7.52%
5Orbis Allan Gray Ltd 7.46%
6PERCEPTIVE ADVISORS LLC 6.29%
7T. Rowe Price 5.02%
8JANUS INVESTMENT FUND 3.97%
9State Street 3.00%
10GEODE CAPITAL MANAGEMENT, LLC 2.34%

Reported Praxis Precision Medicines, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Praxis Precision Medicines, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
Entities affiliated with Janus Henderson Group 9.92% DEF14A
BlackRock 8.35% 13F
FMR (Fidelity) 7.76% 13F
Entities affiliated with Perceptive Advisors 7.16% DEF14A
Perceptive Advisors LLC 7.16% 13G
Baker Bros. Advisors LP 6.29% 13G
Entities affiliated with Point72 5.63% DEF14A
ORBIS INVESTMENT MANAGEMENT LTD 5.48% 13G
Vanguard Group 5.24% 13F
Morgan Stanley 3.19% 13F

Percentages above are of 27,859,514 shares outstanding, as reported by Praxis Precision Medicines, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Praxis Precision Medicines, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Praxis Precision Medicines, Inc.'s shareholder meeting held 2026-06-10, in the 2025-2026 proxy season, 303 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 2,108 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory (non-binding) basis, the compensation of the named executive… — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Praxis Precision Medicines, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-12.

Praxis Precision Medicines, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).